Amphista previews BRD9 degradation findings and BRAMLIE trial design at ASH
Company / institutional announcement · Amphista Therapeutics / Business Wire
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What changed
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Why it may matter
Analysis: Mechanistic evidence may help differentiate non-cereblon/VHL degradation platforms, while early clinical development must establish tolerability, exposure, and meaningful patient benefit.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections